NHS Chair of Pharmacogenetics, The Wolfson Centre for Personalised Medicine, Department of Pharmacology, University of Liverpool, Liverpool, UK.
Clin Pharmacol Ther. 2010 Dec;88(6):862-6. doi: 10.1038/clpt.2010.245. Epub 2010 Oct 27.
The journey from the discovery of a biomarker to its implementation in clinical practice is long and complex. There are many obstacles along the way, including lack of consistent evidence, inadequate validation of the biomarker, inadequate evidence of clinical utility, operational barriers to clinical implementation, and inadequate evidence of operational effectiveness or impact in clinical care. Multipronged approaches, incorporating input from many disciplines working together, will be required to overcome the obstacles to the clinical implementation and to allow the progression of clinical practice from the current paradigm of a one-size-fits-all strategy to more personalized treatment pathways that are more predictable in terms of health gains.
从生物标志物的发现到将其应用于临床实践,这是一个漫长而复杂的过程。在这个过程中存在着许多障碍,包括缺乏一致性证据、生物标志物验证不足、临床实用性证据不足、临床实施的操作障碍,以及在临床护理中缺乏操作有效性或影响的证据。需要采取多管齐下的方法,让来自不同学科的人共同参与,克服临床实施的障碍,使临床实践从目前一刀切的策略模式向更具预测性的个性化治疗途径发展,从而获得更多的健康收益。